Comparative performance of different methods for circulating tumor cell enrichment in metastatic breast cancer patients.
The isolation and analysis of circulating tumor cells (CTC) has the potential to provide minimally invasive diagnostic, prognostic and predictive information. Widespread clinical implementation of CTC analysis has been hampered by a lack of comparative investigation between different analytic method...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2020-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0237308 |
id |
doaj-c0c50f5364e84496ac8f1399137b37e0 |
---|---|
record_format |
Article |
spelling |
doaj-c0c50f5364e84496ac8f1399137b37e02021-03-03T22:01:03ZengPublic Library of Science (PLoS)PLoS ONE1932-62032020-01-01158e023730810.1371/journal.pone.0237308Comparative performance of different methods for circulating tumor cell enrichment in metastatic breast cancer patients.Arik DruckerEvelyn M TehRipsik KostylevaDaniel RaysonSusan DouglasDevanand M PintoThe isolation and analysis of circulating tumor cells (CTC) has the potential to provide minimally invasive diagnostic, prognostic and predictive information. Widespread clinical implementation of CTC analysis has been hampered by a lack of comparative investigation between different analytic methodologies in clinically relevant settings. The objective of this study was to evaluate four different CTC isolation techniques-those that rely on surface antigen expression (EpCAM or CD45 using DynaBeads® or EasySep™ systems) or the biophysical properties (RosetteSep™ or ScreenCell®) of CTCs. These were evaluated using cultured cells in order to calculate isolation efficiency at various levels including; inter-assay and inter-operator variability, protocol complexity and turn-around time. All four techniques were adequate at levels above 100 cells/mL which is commonly used for the evaluation of new isolation techniques. Only the RosetteSep™ and ScreenCell® techniques were found to provide adequate sensitivity at a level of 10 cells/mL. These techniques were then applied to the isolation and analysis of circulating tumor cells blood drawn from metastatic breast cancer patients where CTCs were detected in 54% (15/28) of MBC patients using the RosetteSep™ and 75% (6/8) with ScreenCell®. Overall, the ScreenCell® method had better sensitivity.https://doi.org/10.1371/journal.pone.0237308 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Arik Drucker Evelyn M Teh Ripsik Kostyleva Daniel Rayson Susan Douglas Devanand M Pinto |
spellingShingle |
Arik Drucker Evelyn M Teh Ripsik Kostyleva Daniel Rayson Susan Douglas Devanand M Pinto Comparative performance of different methods for circulating tumor cell enrichment in metastatic breast cancer patients. PLoS ONE |
author_facet |
Arik Drucker Evelyn M Teh Ripsik Kostyleva Daniel Rayson Susan Douglas Devanand M Pinto |
author_sort |
Arik Drucker |
title |
Comparative performance of different methods for circulating tumor cell enrichment in metastatic breast cancer patients. |
title_short |
Comparative performance of different methods for circulating tumor cell enrichment in metastatic breast cancer patients. |
title_full |
Comparative performance of different methods for circulating tumor cell enrichment in metastatic breast cancer patients. |
title_fullStr |
Comparative performance of different methods for circulating tumor cell enrichment in metastatic breast cancer patients. |
title_full_unstemmed |
Comparative performance of different methods for circulating tumor cell enrichment in metastatic breast cancer patients. |
title_sort |
comparative performance of different methods for circulating tumor cell enrichment in metastatic breast cancer patients. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2020-01-01 |
description |
The isolation and analysis of circulating tumor cells (CTC) has the potential to provide minimally invasive diagnostic, prognostic and predictive information. Widespread clinical implementation of CTC analysis has been hampered by a lack of comparative investigation between different analytic methodologies in clinically relevant settings. The objective of this study was to evaluate four different CTC isolation techniques-those that rely on surface antigen expression (EpCAM or CD45 using DynaBeads® or EasySep™ systems) or the biophysical properties (RosetteSep™ or ScreenCell®) of CTCs. These were evaluated using cultured cells in order to calculate isolation efficiency at various levels including; inter-assay and inter-operator variability, protocol complexity and turn-around time. All four techniques were adequate at levels above 100 cells/mL which is commonly used for the evaluation of new isolation techniques. Only the RosetteSep™ and ScreenCell® techniques were found to provide adequate sensitivity at a level of 10 cells/mL. These techniques were then applied to the isolation and analysis of circulating tumor cells blood drawn from metastatic breast cancer patients where CTCs were detected in 54% (15/28) of MBC patients using the RosetteSep™ and 75% (6/8) with ScreenCell®. Overall, the ScreenCell® method had better sensitivity. |
url |
https://doi.org/10.1371/journal.pone.0237308 |
work_keys_str_mv |
AT arikdrucker comparativeperformanceofdifferentmethodsforcirculatingtumorcellenrichmentinmetastaticbreastcancerpatients AT evelynmteh comparativeperformanceofdifferentmethodsforcirculatingtumorcellenrichmentinmetastaticbreastcancerpatients AT ripsikkostyleva comparativeperformanceofdifferentmethodsforcirculatingtumorcellenrichmentinmetastaticbreastcancerpatients AT danielrayson comparativeperformanceofdifferentmethodsforcirculatingtumorcellenrichmentinmetastaticbreastcancerpatients AT susandouglas comparativeperformanceofdifferentmethodsforcirculatingtumorcellenrichmentinmetastaticbreastcancerpatients AT devanandmpinto comparativeperformanceofdifferentmethodsforcirculatingtumorcellenrichmentinmetastaticbreastcancerpatients |
_version_ |
1714813865556967424 |